Cardiol Therapeutics Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Cardiol Therapeutics Stock Summary

Cardiol Therapeutics competes with Flora Growth, ABVC Biopharma, Indaptus Therapeutics, HCW Biologics, and Painreform. Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease . Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Cardiol Therapeutics is traded on NASDAQ Exchange in the United States.

Cardiol Therapeutics Key Financial Ratios

Cardiol Therapeutics Key Balance Sheet Accounts

Cardiol Therapeutics Key Income Statement Accounts

Cardiol Therapeutics Key Cash Accounts

Cardiol Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cardiol Therapeutics's current stock value. Our valuation model uses many indicators to compare Cardiol Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cardiol Therapeutics competition to find correlations between indicators driving Cardiol Therapeutics's intrinsic value. More Info.Cardiol Therapeutics Class is number one stock in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Cardiol Therapeutics' Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cardiol Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Cardiol Therapeutics Systematic Risk

Today, most investors in Cardiol Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cardiol Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cardiol Therapeutics growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Cardiol Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cardiol Therapeutics Class. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cardiol Therapeutics Class based on widely used predictive technical indicators. In general, we focus on analyzing Cardiol Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cardiol Therapeutics's daily price indicators and compare them against related drivers.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.